DK3204378T6 - N-pyridinylacetamidderivater som hæmmere af wnt-signaleringsbanen - Google Patents

N-pyridinylacetamidderivater som hæmmere af wnt-signaleringsbanen Download PDF

Info

Publication number
DK3204378T6
DK3204378T6 DK15782041.6T DK15782041T DK3204378T6 DK 3204378 T6 DK3204378 T6 DK 3204378T6 DK 15782041 T DK15782041 T DK 15782041T DK 3204378 T6 DK3204378 T6 DK 3204378T6
Authority
DK
Denmark
Prior art keywords
pyridinylacetamid
inhibitors
derivatives
signaling pathway
wnt signaling
Prior art date
Application number
DK15782041.6T
Other languages
English (en)
Other versions
DK3204378T3 (da
Inventor
Inder Bhamra
Matilda Bingham
Richard Testar
Louise Sargent
Craig Donoghue
Original Assignee
Redx Pharma Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1417829.7A external-priority patent/GB201417829D0/en
Priority claimed from GBGB1511387.1A external-priority patent/GB201511387D0/en
Application filed by Redx Pharma Plc filed Critical Redx Pharma Plc
Publication of DK3204378T3 publication Critical patent/DK3204378T3/da
Application granted granted Critical
Publication of DK3204378T6 publication Critical patent/DK3204378T6/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
DK15782041.6T 2014-10-08 2015-10-08 N-pyridinylacetamidderivater som hæmmere af wnt-signaleringsbanen DK3204378T6 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1417829.7A GB201417829D0 (en) 2014-10-08 2014-10-08 Compounds
GBGB1511387.1A GB201511387D0 (en) 2015-06-29 2015-06-29 Compounds
PCT/GB2015/052939 WO2016055786A1 (en) 2014-10-08 2015-10-08 N-pyridinyl acetamide derivatives as inhibitors of the wnt signalling pathway

Publications (2)

Publication Number Publication Date
DK3204378T3 DK3204378T3 (da) 2019-10-21
DK3204378T6 true DK3204378T6 (da) 2022-07-18

Family

ID=54337304

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15782041.6T DK3204378T6 (da) 2014-10-08 2015-10-08 N-pyridinylacetamidderivater som hæmmere af wnt-signaleringsbanen

Country Status (23)

Country Link
US (4) US10047079B2 (da)
EP (1) EP3204378B3 (da)
JP (2) JP6722178B2 (da)
KR (1) KR102525131B1 (da)
CN (1) CN107108565B (da)
AU (1) AU2015329784C1 (da)
CA (1) CA2960446C (da)
CY (1) CY1122243T1 (da)
DK (1) DK3204378T6 (da)
EA (1) EA034822B9 (da)
ES (1) ES2754349T7 (da)
HR (1) HRP20191826T4 (da)
HU (1) HUE046914T2 (da)
IL (1) IL251131B (da)
LT (1) LT3204378T (da)
MX (1) MX2017004637A (da)
PH (1) PH12017500611A1 (da)
PL (1) PL3204378T6 (da)
PT (1) PT3204378T (da)
SG (1) SG11201701837UA (da)
SI (1) SI3204378T1 (da)
WO (1) WO2016055786A1 (da)
ZA (1) ZA201701842B (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2960446C (en) 2014-10-08 2023-09-19 Redx Pharma Plc N-pyridinyl acetamide derivatives as inhibitors of the wnt signalling pathway
SG11201702142UA (en) 2014-10-08 2017-04-27 Redx Pharma Plc N-pyridinyl acetamide derivatives as wnt signalling pathway inhibitors
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
US10793544B2 (en) 2016-09-01 2020-10-06 The Board Of Regents Of The University Of Texas System Disubstituted and trisubstituted 1,2,3-triazoles as Wnt inhibitors
WO2018165520A1 (en) 2017-03-10 2018-09-13 Vps-3, Inc. Metalloenzyme inhibitor compounds
JP2019064975A (ja) * 2017-10-03 2019-04-25 国立大学法人 熊本大学 抗がん剤
JP7184383B2 (ja) * 2018-02-01 2022-12-06 ザ・ユニバーシティ・オブ・シドニー 抗癌性化合物
IL277071B1 (en) 2018-03-08 2024-03-01 Incyte Corp Aminopyrizine diol compounds as PI3K–y inhibitors
WO2020010003A1 (en) 2018-07-02 2020-01-09 Incyte Corporation AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
US10961534B2 (en) 2018-07-13 2021-03-30 University of Pittsburgh—of the Commonwealth System of Higher Education Methods of treating porphyria
EP4076448A4 (en) 2019-12-20 2024-03-27 Tenaya Therapeutics Inc FLUOROALKYLATED OXADIAZOLES AND THEIR USES
US20230404985A1 (en) * 2020-11-02 2023-12-21 Icahn School Of Medicine At Mount Sinai Methods of treating tumors and cancers having dysregulated wnt signaling pathways
GB202100526D0 (en) 2021-01-15 2021-03-03 Redx Pharma Plc Pharmaceutical formulation

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0946508B1 (en) 1996-12-23 2009-09-23 Bristol-Myers Squibb Pharma Company NITROGEN CONTAINING HETEROAROMATICS AS FACTOR Xa INHIBITORS
JP2001506271A (ja) 1996-12-23 2001-05-15 デュポン ファーマシューティカルズ カンパニー Ｘａ因子阻害剤としての酸素またはイオウを含む複素環式芳香族化合物
GB0226583D0 (en) 2002-11-14 2002-12-18 Cyclacel Ltd Compounds
SE0203654D0 (sv) 2002-12-09 2002-12-09 Astrazeneca Ab New compounds
CN1747936A (zh) * 2003-02-12 2006-03-15 特兰斯泰克制药公司 作为治疗试剂的取代吡咯衍生物
EP1802608A1 (en) * 2004-10-12 2007-07-04 AstraZeneca AB Quinazoline derivatives for use against cancer
JP2010526078A (ja) * 2007-04-30 2010-07-29 ジェネンテック， インコーポレイテッド Ｗｎｔシグナル伝達のピラゾールインヒビター
CA2707492A1 (en) 2007-12-13 2009-06-18 Amgen Inc. Gamma secretase modulators
UA103918C2 (en) * 2009-03-02 2013-12-10 Айерем Элелси N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
US8993612B2 (en) 2009-10-08 2015-03-31 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer
UY33469A (es) * 2010-06-29 2012-01-31 Irm Llc Y Novartis Ag Composiciones y metodos para modular la via de señalizacion de wnt
ES2968742T3 (es) * 2012-02-28 2024-05-13 Novartis Ag Selección de pacientes con cáncer para la administración de inhibidores de la señalización Wnt utilizando el estado mutacional de Rnf43
GB2513403A (en) 2013-04-26 2014-10-29 Agency Science Tech & Res WNT pathway modulators
SG11201702142UA (en) 2014-10-08 2017-04-27 Redx Pharma Plc N-pyridinyl acetamide derivatives as wnt signalling pathway inhibitors
CA2960446C (en) 2014-10-08 2023-09-19 Redx Pharma Plc N-pyridinyl acetamide derivatives as inhibitors of the wnt signalling pathway

Also Published As

Publication number Publication date
DK3204378T3 (da) 2019-10-21
WO2016055786A1 (en) 2016-04-14
US20210046076A1 (en) 2021-02-18
PL3204378T6 (pl) 2022-09-12
AU2015329784C1 (en) 2020-10-15
EA201790637A1 (ru) 2017-10-31
AU2015329784B2 (en) 2019-08-22
EA034822B9 (ru) 2020-10-23
EP3204378B1 (en) 2019-07-10
HRP20191826T4 (hr) 2022-08-05
CN107108565B (zh) 2019-08-23
US10047079B2 (en) 2018-08-14
CA2960446C (en) 2023-09-19
US20230365549A1 (en) 2023-11-16
EA034822B1 (ru) 2020-03-25
LT3204378T (lt) 2019-10-25
CA2960446A1 (en) 2016-04-14
AU2015329784A1 (en) 2017-03-30
JP2020090542A (ja) 2020-06-11
BR112017006476A2 (pt) 2017-12-19
CY1122243T1 (el) 2020-11-25
EP3204378B3 (en) 2022-05-25
JP6722178B2 (ja) 2020-07-15
KR102525131B1 (ko) 2023-04-24
IL251131B (en) 2020-07-30
US20180319788A1 (en) 2018-11-08
PT3204378T (pt) 2019-11-12
NZ729820A (en) 2023-09-29
US10793560B2 (en) 2020-10-06
US20170275276A1 (en) 2017-09-28
SI3204378T1 (sl) 2019-12-31
JP2017530183A (ja) 2017-10-12
SG11201701837UA (en) 2017-04-27
PL3204378T3 (pl) 2020-03-31
PH12017500611A1 (en) 2017-09-25
EP3204378A1 (en) 2017-08-16
ZA201701842B (en) 2022-05-25
ES2754349T3 (es) 2020-04-17
KR20170063906A (ko) 2017-06-08
HUE046914T2 (hu) 2020-04-28
US11643408B2 (en) 2023-05-09
MX2017004637A (es) 2017-06-30
PL3204378T4 (pl) 2020-03-31
HRP20191826T1 (hr) 2020-01-10
CN107108565A (zh) 2017-08-29
IL251131A0 (en) 2017-04-30
ES2754349T7 (es) 2022-09-19

Similar Documents

Publication Publication Date Title
DK3204381T3 (da) N-pyridinylacetamidderivater som wnt-signaleringsbanehæmmere
DK3442980T3 (da) Heterocykliske forbindelser som ret-kinase-hæmmere
DK3464271T3 (da) Pyrazolderivater som plasma-kallikreininhibitorer
DK3204378T6 (da) N-pyridinylacetamidderivater som hæmmere af wnt-signaleringsbanen
DK3371190T3 (da) Heterocykliske forbindelser som pi3k-gamma-inhibitorer
DK3302448T3 (da) Erstattede heterocyclylafledninger som cdk-inhibitore
DK3102576T3 (da) Dihydropyrrolopyridininhibitorer af ror-gamma
DK3105218T3 (da) Cyclopropylaminer som lsd1-inhibitorer
DK3105226T3 (da) Cyclopropylaminer som lsd1-inhibitorer
DK3119762T3 (da) Benzimidazol-derivater som erbb-tyrosin-kinase-inhibitorer til behandlingen af kræft
DK3357919T3 (da) Aromatiske heterocykliske forbindelser som antiinflammatoriske forbindelser
DK3160956T3 (da) Inhibitorer af lysin-specifik demethylase-1
DK3094631T3 (da) Pyrimidinyloxybenzenderivater som herbicider
DK3164380T3 (da) Hæmmere af lysinspecifik demethylase-1
DK3348556T3 (da) Heteroarylamider som hæmmere af proteinaggregering
DK3536324T3 (da) 4-oxo-3,4-dihydro-1,2,3-benzotriaziner som modulatorer af gpr139
DK3114120T3 (da) Tetrazolon-substituerede dihydropyridinon-mgat2-hæmmere
DK3204352T3 (da) Hæmmere af lysin-gingipain
DK3418273T3 (da) Derivater af flavagliner
DK3137658T3 (da) Anvendelse af kendte forbindelser som d-aminosyreoxidase-inhibitorer
DK3319970T3 (da) Pyrido-oxazinonderivater som tnap-hæmmere
DK2913321T3 (da) Hidtil ukendte cannabigerolderivater
DK3233839T3 (da) Heterocyclylkoblede imidazopyridazinderivater som pi3k-beta-inhibitorer
DK3484875T3 (da) Pyrazolylaminobenzimidazolderivater som JAK-hæmmere
DK3224253T3 (da) Bis(sulfonamid)-derivater og deres anvendelse som mpges-inhibitorer